<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bacterial adherence and other virulence factors for urinary tract infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bacterial adherence and other virulence factors for urinary tract infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bacterial adherence and other virulence factors for urinary tract infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alain Meyrier, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bacterial adhesion onto mucosal or urothelial cells is an important phenomenon determining bacterial virulence. Infection in the urinary tract is related in part to the ability of bacteria to adhere and colonize epithelial cells in the gut, perineum, urethra, bladder, renal pelvicalyceal system, and renal interstitium [<a href="#rid1">1-6</a>]. Adhesion is particularly important when infection occurs in an anatomically normal urinary tract [<a href="#rid3">3,5,6</a>], but it is also important in recurrent cystitis and infection complicating indwelling bladder catheters [<a href="#rid7">7,8</a>].</p><p>The pathophysiology of bacterial adhesion in the urinary tract is complex [<a href="#rid9">9</a>]. Uropathogenic Enterobacteriaceae are electronegative and too small to overcome repulsion by the net negative charge of epithelial cells. As a result, bacterial adhesion cannot occur in the absence of fimbriae or other (nonfimbrial) surface adhesion systems. These systems have favorable electrical charge and also promote adhesion via hydrophobicity. Fimbriae allow irreversible attachment to the uroepithelial cell membrane via adhesins [<a href="#rid5">5,6</a>].</p><p>This topic review will primarily consider the role of bacterial adhesion as a virulence determinant of <em>Escherichia coli </em>and <em>Proteus mirabilis</em>, the two most common strains responsible for urinary tract infection (UTI). Virulence factors of <em>E. coli</em> are mainly responsible for promoting progression of the organism from the fecal reservoir into the bladder and occasionally the kidney. In comparison, virulence factors of <em>P. mirabilis</em> can induce UTI but are particularly important for the formation of infectious struvite stones.</p><p>Bacterial virulence is not related to resistance to antimicrobial drugs. As an example, the most adherent strain of <em>E. coli</em> in the patient's intestinal flora is usually sensitive to most antibiotics.</p><p>Multiple host-pathogen interactions are at work in urinary tract infections [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2711214930"><span class="h1">BACTERIAL ADHESION</span><span class="headingEndMark"> — </span>Bacterial adhesion in the urinary tract results from a complex interplay of factors [<a href="#rid11">11</a>]. Uropathogenic <em>E. coli </em>(UPEC) display pili at their surface, which help mediate adhesion:</p><p class="bulletIndent1"><span class="glyph">●</span>UPEC attaches to the uroepithelium through type 1 pili, which bind the receptors uroplakin Ia and IIIa [<a href="#rid9">9</a>]. This binding stimulates signalling pathways that mediate invasion and apoptosis. Binding of type 1 pili to alpha 3 beta 1 integrins also mediates internalization of the bacteria into superficial facet cells to form intracellular bacterial communities or pods. Sublytic concentrations of the pore-forming hemolysin A toxin can inhibit the activation of Akt proteins and lead to host cell apoptosis and exfoliation. Exfoliation of the uroepithelium exposes the underlying transition cells for further UPEC invasion, and the bacteria can reside in these cells as quiescent intracellular reservoirs that may be involved in recurrent infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The tip of pili consists of the adhesion factor PapG that binds to glycosphingolipids of the kidney epithelium [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some UPEC strains also possess type I pili at their surface, which have binding specificity to D-mannosylated receptors, such as the uroplakins of the bladder [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IV pili form another class of polymeric adhesive surface structures expressed by different gram-negative bacteria [<a href="#rid14">14</a>]. They have the ability to retract through the bacterial cell wall while their tip remains attached to its target surface, allowing for "twitching motility," a flagella-independent mode of motility important for colonization of host surfaces [<a href="#rid15">15</a>]. These pili are composed of thousands of copies of the major pilin protein, which are synthetized in the bacterial cytoplasm, translocated across the inner membrane, and proteolytically processed. The assembled pili then pass through the outer membrane via a channel formed by the secretion protein [<a href="#rid16">16,17</a>]. These pili aggregate to form bundles. </p><p></p><p>In addition to pili, a wide range of bacterial surface adhesins recognize various classes of host molecules (including transmembrane proteins such as integrins or cadherins) or components of the extracellular matrix (such as collagen, fibronectin, laminin, or elastin) [<a href="#rid18">18</a>]. Some of these adhesins, after allowing the binding of bacteria to host cell surfaces, also trigger the internalization of bacteria inside host cells that protects them from antibiotics [<a href="#rid12">12,19</a>]. (See <a class="local">'Adhesins'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">ESCHERICHIA COLI</span><span class="headingEndMark"> — </span>Virulence factors of uropathogenic <em>E. coli</em> include several properties pertaining to a small group of O-serotypes, including O1, O2, O4, O6, O7, O16, O18, and O75 (<a class="graphic graphic_figure graphicRef87632" href="/d/graphic/87632.html" rel="external">figure 1</a>) [<a href="#rid20">20</a>]. The uropathogenicity of these serotypes can be illustrated by their prevalence in different populations. They are present in approximately 28 percent of isolates from the normal fecal flora; in comparison, they are responsible for roughly 80 percent of cases of pyelonephritis, 60 percent of cystitis, and 30 percent of asymptomatic bacteriuria [<a href="#rid21">21</a>].</p><p>A study typing <em>E. coli</em> strains in women and their sexual partners showed that <em>E. coli</em> strains that had caused urinary tract infection were nine times more likely to have been passed between sexual partners than strains from women without infection [<a href="#rid22">22</a>]. Strains with P pili were also more likely to have been shared between partners.</p><p class="headingAnchor" id="H3"><span class="h2">Adhesins</span><span class="headingEndMark"> — </span>There are several other factors that affect the uropathogenicity of <em>E. coli</em>. Of greatest importance is the presence of adhesins on the tip of bacterial fimbriae (also called pili) and on the bacterial surface itself (nonfimbrial adhesins) (<a class="graphic graphic_table graphicRef55155" href="/d/graphic/55155.html" rel="external">table 1</a>) [<a href="#rid23">23,24</a>]. Most adhesins are lectins that recognize binding site conformations provided by oligosaccharide sequences present on the epithelial cell surface.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fimbrial adhesins</strong> – Two major fimbrial adherence systems have been identified in E. coli strains associated with UTI: pap and sfa (<a class="graphic graphic_table graphicRef55155" href="/d/graphic/55155.html" rel="external">table 1</a>). The PAP adhesin, for example, is present on the tip of P fimbriae [<a href="#rid23">23-27</a>]. The term P fimbriae stems from the fact that the PAP adhesin recognizes the human digalactoside P blood group determinants on human erythrocytes and urothelial cells, leading to increased adhesion (<a class="graphic graphic_picture graphicRef70223" href="/d/graphic/70223.html" rel="external">picture 1</a>) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">The binding of P fimbriae to blood group determinants has important implications for host susceptibility to infection. Women who are nonsecretors of histo-blood group antigens show increased in vitro binding of <em>E. coli</em> to urothelial cells and are more likely to have recurrent urinary tract infections [<a href="#rid28">28</a>]. Nonsecretors may have abnormal processing of gal-globoside glycolipid receptors resulting in the production of proteins that bind with more avidity to E. coli [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonfimbrial adhesins</strong> – Nonfimbrial adhesins encompass a diverse range of proteins, including AFA (<a class="graphic graphic_table graphicRef55155" href="/d/graphic/55155.html" rel="external">table 1</a>). Other important adhesins include the AT (autotransporter) family of trimeric proteins [<a href="#rid30">30</a>]. Two of these proteins are highly homologous to the <em>E. coli</em> K-12 antigen 43 (Ag43a). This antigen promotes strong biofilm growth and its expression is associated with long-term <em>E. coli</em> persistence in the bladder.</p><p></p><p>The presence of adhesins in a given <em>E. coli</em> strain can be detected by phenotypic methods such as hemagglutination or agglutination of latex beads. However, phenotypic expression of uropathogenicity can be lost in cultured bacteria. As a result, genetic and molecular methods have been devised to identify the pap, afa, and sfa operons in the bacterial chromosomal DNA [<a href="#rid26">26</a>]. This has permitted more accurate estimate of the frequency of these adhesins in urinary tract infections.</p><p>The frequency of the pap, sfa and afa operons is approximately 75, 25, and 10 percent, respectively in pyelonephritis, 45, 20, and 12 percent in cystitis, and 24, 27, and 0 percent in asymptomatic bacteriuria [<a href="#rid25">25</a>]. We have detected at least one adhesin system in virtually all young females with primary pyelonephritis and a normal urinary tract [<a href="#rid31">31</a>].</p><p>These observations have led us and other investigators to suggest that patients with UTI who are infected with non-uropathogenic bacteria (ie, without fimbriae) should undergo a uroradiologic evaluation to detect an anatomic abnormality predisposing to infection such as intermittent reflux, neuromuscular dysfunction of the bladder or bladder neck obstruction [<a href="#rid31">31,32</a>]. The clinical relevance of this suggestion is at present limited since genotypic methods to detect adhesins are restricted to a few specialized laboratories.</p><p class="headingAnchor" id="H5514840"><span class="h2">Fimbriae</span><span class="headingEndMark"> — </span>In addition to adhesins, which influence the likelihood of infection, fimbriae have other virulence properties. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Type I fimbriae in <em>E. coli</em> serve as virulence factors by promoting persistence of the infection and by increasing the inflammatory response to the infection [<a href="#rid29">29</a>]. Children who have acute pyelonephritis due to these organisms have been noted to have a more rapid onset of infection, higher fever, longer duration of fever, and a higher white blood cell count than those infected with other organisms [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a murine model of pyelonephritis, Dr fimbriae in <em>E. coli</em> promoted renal tropism and prevented the clearance of infection. This effect was mediated by binding to renal tubular basement membranes and Bowman's capsule via decay accelerating factor (a complement regulatory receptor) and collagen type IV [<a href="#rid23">23,25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type I fimbriae appear to contribute to the ability of uropathogenic <em>E. coli</em> to impair ureteric contractility, which is thought to be instrumental in limiting ascension of bacteria from the bladder to kidneys [<a href="#rid34">34,35</a>].</p><p></p><p>The role of fimbriae has potentially important therapeutic implications for prevention of urinary tract infections. In a murine model, for example, animals vaccinated against the FimH adhesin developed antibodies that inhibited <em>E. coli</em> binding to human bladder cells in vitro and reduced colonization of the bladder mucosa by more than 99 percent [<a href="#rid36">36</a>]. The latter effect was associated with IgG anti-FimH antibodies in the urine. Passive immunization with sera from these animals also prevented colonization. In one study in monkeys, inoculation with <em>E. coli</em> FimH adhesin-chaperone complex mixed with MF59 adjuvant elicited a strong IgG antibody response to FimH [<a href="#rid37">37</a>]. After a pathogenic <em>E. coli</em> challenge, three of four vaccinated monkeys were protected from bacteriuria and pyuria whereas the four control monkeys were infected. </p><p>However, vaccination against FimH may be more complicated than expected, as use of certain fimbrial antigens may induce a conformation-specific immune response that has enhancing rather than inhibiting effects. As an example, the lectin domain of FimH can shift between a low- to a high-affinity conformation when interacting with its receptor. In an animal study, immunization with the lectin domain induced antibodies that predominantly recognized the high-affinity conformation [<a href="#rid38">38</a>]. Instead of inhibiting adhesive function, these antibodies enhanced bacterial adhesion to urothelial cells. Furthermore, bound antibodies were released when the FimH adhesin naturally converted from the high- to low-affinity state.</p><p>Two vaccine formulations thus far include a daily oral capsule containing membrane proteins from 18 <em>E. coli</em> strains and a vaginal suppository containing ten heat-killed uropathogenic <em>E. coli</em> strains; however, they require frequent administration [<a href="#rid39">39</a>]. These are both available in Switzerland. There are no vaccines against uropathogenic <em>E. coli</em> licensed in the United States. Research towards their development is ongoing, including evaluation of a tetravalent <em>E. coli</em> bioconjugate vaccine that elicited functional antibody responses against all vaccine serotypes [<a href="#rid40">40</a>] and experimental studies in mice that support the potential for adjuvanted UPEC antigen vaccine that can be administered intranasally [<a href="#rid41">41</a>]. </p><p>It is likely that antibiotic prophylaxis of recurrent UTI with low (non-bactericidal) dose antibiotics reduces the frequency of relapses through diminished fimbrial adhesion to the urothelium.</p><p>Daily ingestion of cranberry juice, commonly prescribed in women with recurrent UTI, has no effect on fimbrial adhesion to the urothelium [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Other virulence factors</span><span class="headingEndMark"> — </span>Several additional factors also affect the virulence of <em>E. coli</em> [<a href="#rid20">20</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of flagellae, which are necessary for motility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Production of a hemolysin, which induces formation of pores in the cell membrane, and aerobactin, a siderophore necessary for iron uptake in the iron-poor environment of the urinary tract.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistance to plasma bactericidal properties.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interaction with vaginal microbiota – Recurrent UTI can be triggered by transient exposure to vaginal bacteria, specifically <em>Gardnerella vaginalis </em>[<a href="#rid43">43</a>]. This observation suggests that UTI pathogenesis can be driven by short-term urinary tract exposure to vaginal microbiota, which are not themselves traditionally considered uropathogenic.</p><p></p><p class="headingAnchor" id="H17016903"><span class="h2">Entry into urothelial cells</span><span class="headingEndMark"> — </span>Uropathogenic <em>E. coli</em> (UPEC) are able to invade urothelial cells to replicate within them [<a href="#rid6">6</a>]. Entry into bladder epithelial cells provides UPEC with a protected niche where the bacteria can persist, quiescent, for long periods, unperturbed by host defenses and protected from antibiotic therapy. These reservoirs likely serve as sources of seemingly recurrent infections [<a href="#rid44">44,45</a>].</p><p class="headingAnchor" id="H1886519284"><span class="h2">Biofilms</span><span class="headingEndMark"> — </span>Bacterial adhesion to cell surfaces is a key element in the formation of biofilms<em> </em>(ie, extracellular,<em> </em>matrix-enclosed, microbial assemblies that can adhere to biological or nonbiological surfaces, especially foreign material such as indwelling catheters). Biofilm formation entails a protected mode of growth that allows bacterial survival in a hostile environment. These matrix-embedded bacterial aggregates are more resistant to host defenses or antibiotic treatments. The in vivo role of biofilms during bacterial infections is an active field of research [<a href="#rid46">46,47</a>]. </p><p class="headingAnchor" id="H7"><span class="h1">PROTEUS MIRABILIS</span><span class="headingEndMark"> — </span><em>P. mirabilis </em>is armed with various virulence factors, including the production of hemolysin and IgA protease, iron acquisition, flagella, fimbriae and, most importantly, the secretion of urease (<a class="graphic graphic_figure graphicRef87632" href="/d/graphic/87632.html" rel="external">figure 1</a>) [<a href="#rid48">48</a>]. Urease is a high molecular weight cytoplasmic enzyme that hydrolyzes urea to ammonia and carbon dioxide. Ammonia combines with hydrogen to form ammonium; the ensuing reduction in free hydrogen ion concentration leads to alkalinization with the urine pH being well above 7.0 and sometimes as high as 9.0.</p><p>The alkaline urine promotes the precipitation of phosphate, carbonate and magnesium, leading to the formation of struvite stones that often form large staghorn calculi. These stones contain a mixture of a proteinaceous matrix, leukocytes, struvite and bacteria. This process is self-perpetuating since the Proteus-contaminated stone is a permanent source of bacteria. In addition, its presence within the urinary tract leads to urinary stasis, which promotes further bacterial multiplication, urinary alkalinization, and the deposition of new layers of struvite. (See  <a class="medical medical_review" href="/d/html/7372.html" rel="external">"Kidney stones in adults: Struvite (infection) stones"</a>.)</p><p>In terms of bacterial adhesion, <em>P. mirabilis</em> produces at least four types of fimbriae that do not appear to be absolutely required for the induction of infection [<a href="#rid48">48</a>]. At least two fimbrial systems may contribute to urinary tract colonization: the MR/P fimbriae for bladder and kidney infection; and the PMF fimbriae for bladder infection.</p><p>The acquisition of a particular phenotype known as "swarm cell differentiation" that facilitates <em>P. mirabilis</em> ascent into the urinary tract has also been identified as a factor in uropathogenicity [<a href="#rid49">49</a>]. It is characterized by the formation of very long flagellae. Mice inoculated with wild type Proteus strains that are endowed with the "swarm" phenotype have a higher mortality rate than those inoculated with vegetative strains. Bladder inoculation with the "swarm" type of Proteus significantly increases the incidence of pyelonephritis. The relevance of this phenomenon in human UTI remains to be determined.</p><p>Studies of vaccination with Proteus fimbrial proteins have been conducted in animals [<a href="#rid50">50</a>]. As an example, intranasal immunization with the N-terminal domain of the tip adhesin of MR/P fimbriae was effective in preventing <em>P. mirabilis</em> urinary tract infection in mice. </p><p class="headingAnchor" id="H8"><span class="h1">STAPHYLOCOCCUS SAPROPHYTICUS</span><span class="headingEndMark"> — </span><em>Staphylococcus saprophyticus</em> is a common cause of UTI, particularly cystitis in young, sexually active women [<a href="#rid51">51,52</a>]. It is also an infrequent cause of acute pyelonephritis [<a href="#rid31">31,53</a>]. <em>S. saprophyticus</em> adheres strongly to the urothelium, a process that appears to be linked to a lactosamine residue [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H5514776"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Adhesion onto mucosal or urothelial cells is an important phenomenon determining bacterial virulence of uropathogenic Enterobacteriaceae and relies upon the presence fimbriae or other surface adhesion systems (<a class="graphic graphic_figure graphicRef87632" href="/d/graphic/87632.html" rel="external">figure 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <em>Escherichia coli</em>, adhesins that are located on the tip of bacterial fimbriae or on the bacterial surface itself bind to target sites on host cells and help mediate uropathogenicity (<a class="graphic graphic_table graphicRef55155" href="/d/graphic/55155.html" rel="external">table 1</a>). Virtually all cases of <em>E. coli</em> pyelonephritis in young women with a normal urinary tract are caused by isolates that possess at least one adhesin system. The fimbriae themselves also contribute to virulence through other mechanisms and are an attractive target for vaccination strategies. (See <a class="local">'Escherichia coli'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The secretion of urease by <em>Proteus mirabilis</em> is an important virulence factor that leads to alkalinization of the urine and formation of stones that contain a proteinaceous matrix, leukocytes, struvite, and bacteria. These stones are a permanent source of bacteria. (See <a class="local">'Proteus mirabilis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schoolrik GK. How Escherichia coli infects the urinary tract. N Engl J Med 1989; 320:804.</a></li><li><a class="nounderline abstract_t">Svanborg Edén C, Hausson S, Jodal U, et al. Host-parasite interaction in the urinary tract. J Infect Dis 1988; 157:421.</a></li><li><a class="nounderline abstract_t">Roberts JA. Etiology and pathophysiology of pyelonephritis. Am J Kidney Dis 1991; 17:1.</a></li><li><a class="nounderline abstract_t">Roberts JA. Bacterial adherence and urinary tract infection. South Med J 1987; 80:347.</a></li><li><a class="nounderline abstract_t">Oelschlaeger TA, Dobrindt U, Hacker J. Virulence factors of uropathogens. Curr Opin Urol 2002; 12:33.</a></li><li><a class="nounderline abstract_t">Mulvey MA. Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 2002; 4:257.</a></li><li><a class="nounderline abstract_t">Roberts JA, Fussell EN, Kaack MB. Bacterial adherence to urethral catheters. J Urol 1990; 144:264.</a></li><li><a class="nounderline abstract_t">Reid G, van der Mei HC, Tieszer C, Busscher HJ. Uropathogenic Escherichia coli adhere to urinary catheters without using fimbriae. FEMS Immunol Med Microbiol 1996; 16:159.</a></li><li><a class="nounderline abstract_t">Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010; 8:26.</a></li><li><a class="nounderline abstract_t">Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7:430.</a></li><li><a class="nounderline abstract_t">Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect 2015; 17:173.</a></li><li><a class="nounderline abstract_t">Pizarro-Cerdá J, Cossart P. Bacterial adhesion and entry into host cells. Cell 2006; 124:715.</a></li><li><a class="nounderline abstract_t">Kline KA, Fälker S, Dahlberg S, et al. Bacterial adhesins in host-microbe interactions. Cell Host Microbe 2009; 5:580.</a></li><li><a class="nounderline abstract_t">Roberts JA, Marklund BI, Ilver D, et al. The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci U S A 1994; 91:11889.</a></li><li><a class="nounderline abstract_t">Mattick JS. Type IV pili and twitching motility. Annu Rev Microbiol 2002; 56:289.</a></li><li><a class="nounderline abstract_t">Lillington J, Geibel S, Waksman G. Biogenesis and adhesion of type 1 and P pili. Biochim Biophys Acta 2014; 1840:2783.</a></li><li><a class="nounderline abstract_t">Melville S, Craig L. Type IV pili in Gram-positive bacteria. Microbiol Mol Biol Rev 2013; 77:323.</a></li><li><a class="nounderline abstract_t">Cossart P, Roy CR. Manipulation of host membrane machinery by bacterial pathogens. Curr Opin Cell Biol 2010; 22:547.</a></li><li><a class="nounderline abstract_t">Chagnot C, Listrat A, Astruc T, Desvaux M. Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. Cell Microbiol 2012; 14:1687.</a></li><li><a class="nounderline abstract_t">Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991; 4:80.</a></li><li><a class="nounderline abstract_t">Johnson JR, Roberts PL, Stamm WE. P fimbriae and other virulence factors in Escherichia coli urosepsis: association with patients' characteristics. J Infect Dis 1987; 156:225.</a></li><li><a class="nounderline abstract_t">Foxman B, Manning SD, Tallman P, et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol 2002; 156:1133.</a></li><li><a class="nounderline abstract_t">Servin AL. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev 2005; 18:264.</a></li><li><a class="nounderline abstract_t">Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int 2007; 72:19.</a></li><li><a class="nounderline abstract_t">Le Bouguénec C, Lalioui L, du Merle L, et al. Characterization of AfaE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens. J Clin Microbiol 2001; 39:1738.</a></li><li><a class="nounderline abstract_t">Le Bouguenec C, Archambaud M, Labigne A. Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol 1992; 30:1189.</a></li><li><a class="nounderline abstract_t">Kuehn MJ, Heuser J, Normark S, Hultgren SJ. P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature 1992; 356:252.</a></li><li><a class="nounderline abstract_t">Stapleton A, Nudelman E, Clausen H, et al. Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J Clin Invest 1992; 90:965.</a></li><li><a class="nounderline abstract_t">Goluszko P, Moseley SL, Truong LD, et al. Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis. J Clin Invest 1997; 99:1662.</a></li><li><a class="nounderline abstract_t">Valle J, Mabbett AN, Ulett GC, et al. UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli. J Bacteriol 2008; 190:4147.</a></li><li><a class="nounderline abstract_t">Meyrier A, Condamin MC, Fernet M, et al. Frequency of development of early cortical scarring in acute primary pyelonephritis. Kidney Int 1989; 35:696.</a></li><li><a class="nounderline abstract_t">Connell I, Agace W, Klemm P, et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 1996; 93:9827.</a></li><li><a class="nounderline abstract_t">Hanson LA. Prognostic indicators in childhood urinary infections. Kidney Int 1982; 21:659.</a></li><li><a class="nounderline abstract_t">Floyd RV, Upton M, Hultgren SJ, et al. Escherichia coli-mediated impairment of ureteric contractility is uropathogenic E. coli specific. J Infect Dis 2012; 206:1589.</a></li><li><a class="nounderline abstract_t">Nicolle LE. Terra incognito: the ureter in urinary tract infection. J Infect Dis 2012; 206:1494.</a></li><li><a class="nounderline abstract_t">Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997; 276:607.</a></li><li><a class="nounderline abstract_t">Langermann S, Möllby R, Burlein JE, et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000; 181:774.</a></li><li><a class="nounderline abstract_t">Tchesnokova V, Aprikian P, Kisiela D, et al. Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli. Infect Immun 2011; 79:3895.</a></li><li><a class="nounderline abstract_t">Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 2010; 78:568.</a></li><li><a class="nounderline abstract_t">Huttner A, Hatz C, van den Dobbelsteen G, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017; 17:528.</a></li><li><a class="nounderline abstract_t">Forsyth VS, Himpsl SD, Smith SN, et al. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection. mBio 2020; 11.</a></li><li><a class="nounderline abstract_t">Stapleton AE, Dziura J, Hooton TM, et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc 2012; 87:143.</a></li><li><a class="nounderline abstract_t">Stone L. Infection: Brief encounter: UTI triggered by vaginal microbiota. Nat Rev Urol 2017; 14:328.</a></li><li><a class="nounderline abstract_t">Dhakal BK, Kulesus RR, Mulvey MA. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest 2008; 38 Suppl 2:2.</a></li><li><a class="nounderline abstract_t">Schulz WA. Uropathogenic bacteria leave a mark. Lab Invest 2011; 91:816.</a></li><li><a class="nounderline abstract_t">Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2:95.</a></li><li><a class="nounderline abstract_t">Bjarnsholt T, Alhede M, Alhede M, et al. The in vivo biofilm. Trends Microbiol 2013; 21:466.</a></li><li><a class="nounderline abstract_t">Mobley HL, Island MD, Massad G. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis. Kidney Int Suppl 1994; 47:S129.</a></li><li><a class="nounderline abstract_t">Allison C, Emödy L, Coleman N, Hughes C. The role of swarm cell differentiation and multicellular migration in the uropathogenicity of Proteus mirabilis. J Infect Dis 1994; 169:1155.</a></li><li><a class="nounderline abstract_t">Li X, Lockatell CV, Johnson DE, et al. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infect Immun 2004; 72:66.</a></li><li><a class="nounderline abstract_t">Latham RH, Running K, Stamm WE. Urinary tract infections in young adult women caused by Staphylococcus saprophyticus. JAMA 1983; 250:3063.</a></li><li><a class="nounderline abstract_t">Hovelius B, Mårdh PA. Staphylococcus saprophyticus as a common cause of urinary tract infections. Rev Infect Dis 1984; 6:328.</a></li><li><a class="nounderline abstract_t">Jordan PA, Iravani A, Richard GA, Baer H. Urinary tract infection caused by Staphylococcus saprophyticus. J Infect Dis 1980; 142:510.</a></li></ol></div><div id="topicVersionRevision">Topic 8055 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564165" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : How Escherichia coli infects the urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3278062" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Host-parasite interaction in the urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1670905" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Etiology and pathophysiology of pyelonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2881359" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bacterial adherence and urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753131" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Virulence factors of uropathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12027955" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adhesion and entry of uropathogenic Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2115595" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bacterial adherence to urethral catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116632" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Uropathogenic Escherichia coli adhere to urinary catheters without using fimbriae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966814" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular mechanisms of Escherichia coli pathogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647992" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Host-pathogen interactions in urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637951" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : How bacterial pathogens colonize their hosts and invade deeper tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497583" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bacterial adhesion and entry into host cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19527885" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bacterial adhesins in host-microbe interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7991552" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142488" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Type IV pili and twitching motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797039" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Biogenesis and adhesion of type 1 and P pili.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24006467" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Type IV pili in Gram-positive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542678" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Manipulation of host membrane machinery by bacterial pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22882798" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672263" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Virulence factors in Escherichia coli urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2885379" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : P fimbriae and other virulence factors in Escherichia coli urosepsis: association with patients' characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480658" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831825" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17396114" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325983" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Characterization of AfaE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349900" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1348107" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522244" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120010" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424525" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651759" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Frequency of development of early cortical scarring in acute primary pyelonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790416" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7047865" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognostic indicators in childhood urinary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23002447" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Escherichia coli-mediated impairment of ureteric contractility is uropathogenic E. coli specific.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23002444" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Terra incognito: the ureter in urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9110982" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669375" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768279" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917708" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Waging war against uropathogenic Escherichia coli: winning back the urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238601" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345645" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305026" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426023" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Infection: Brief encounter: UTI triggered by vaginal microbiota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616559" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617646" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Uropathogenic bacteria leave a mark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15040259" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bacterial biofilms: from the natural environment to infectious diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827084" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The in vivo biofilm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7869662" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8169413" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The role of swarm cell differentiation and multicellular migration in the uropathogenicity of Proteus mirabilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688082" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6644988" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Urinary tract infections in young adult women caused by Staphylococcus saprophyticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6377440" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Staphylococcus saprophyticus as a common cause of urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7192302" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Urinary tract infection caused by Staphylococcus saprophyticus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
